
ORMP
Healthcare · Biotechnology · $161.3M market cap
$3.71-0.32 (-7.9%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | After the close | 0.43 | -0.16 | -137.2% |
| Aug 10, 2026 | After the close | 0.43 | -0.09 | -120.9% |
| Jun 3, 2026 | Time not confirmed | — | 0.91 | — |
| Mar 26, 2026 | After the close | -0.08 | 0.25 | +412.5% |
| Nov 13, 2025 | After the close | -0.04 | 1.13 | +2925.0% |
| Aug 14, 2025 | After the close | -0.04 | 0.31 | +875.0% |
| May 15, 2025 | After the close | -0.03 | -0.19 | -533.3% |
| Mar 4, 2025 | After the close | 0.02 | -0.26 | -1376.0% |
| Nov 7, 2024 | After the close | -0.02 | -0.48 | -2300.0% |
| Aug 14, 2024 | After the close | -0.02 | 0.22 | +1200.0% |
| May 9, 2024 | After the close | 0.02 | 0.04 | +100.0% |
| Mar 6, 2024 | After the close | -0.12 | 0.33 | +375.0% |
| Nov 9, 2023 | After the close | -0.09 | -0.08 |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed…
| +11.1% |
| Aug 10, 2023 | After the close | -0.09 | -0.03 | +66.7% |
| May 11, 2023 | After the close | -0.25 | -0.08 | +68.0% |
| Mar 6, 2023 | After the close | -0.23 | -0.22 | +4.3% |
| Nov 10, 2022 | After the close | -0.26 | -0.18 | +30.8% |
| Aug 10, 2022 | After the close | -0.24 | -0.27 | -12.5% |
| May 12, 2022 | After the close | -0.27 | -0.27 | 0.0% |
| Jan 11, 2022 | After the close | -0.16 | -0.22 | -37.5% |
| Nov 24, 2021 | After the close | -0.18 | -0.21 | -16.7% |
| Jul 14, 2021 | After the close | -0.24 | -0.17 | +29.2% |
| Apr 13, 2021 | After the close | -0.17 | -0.17 | 0.0% |
| Jan 14, 2021 | After the close | -0.19 | -0.23 | -21.1% |
| Nov 24, 2020 | Before the open | -0.21 | -0.12 | +42.9% |
| Jul 7, 2020 | After the close | -0.20 | -0.10 | +50.0% |
| Apr 6, 2020 | After the close | -0.17 | -0.21 | -23.5% |
| Jan 8, 2020 | Time not confirmed | -0.23 | -0.15 | +34.8% |
| Nov 27, 2019 | After the close | -0.24 | -0.13 | +45.8% |
| Jul 10, 2019 | After the close | -0.24 | -0.23 | +4.2% |
| Apr 10, 2019 | After the close | -0.26 | -0.21 | +19.2% |
| Jan 14, 2019 | After the close | -0.19 | -0.25 | -31.6% |
| Nov 28, 2018 | After the close | -0.29 | -0.18 | +37.9% |
| Jul 12, 2018 | After the close | -0.27 | -0.30 | -11.1% |
| Apr 9, 2018 | After the close | -0.29 | -0.20 | +31.0% |
| Jan 11, 2018 | After the close | -0.21 | -0.18 | +14.3% |